Trv Gp Vi LLC Invests $44.77 Billion in Seaport Therapeutics, Inc. $SPTX

Trv Gp Vi LLC purchased a new position in shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) during the 2nd quarter, HoldingsChannel reports. The firm purchased 2,061,222 shares of the company’s stock, valued at approximately $44,769,742,000. Seaport Therapeutics accounts for 19.3% of Trv Gp Vi LLC’s portfolio, making the stock its 2nd largest holding.

Seaport Therapeutics Price Performance

Shares of Seaport Therapeutics stock opened at $23.97 on Wednesday. The stock has a market cap of $1.28 billion and a P/E ratio of -1.98. Seaport Therapeutics, Inc. has a 1 year low of $14.85 and a 1 year high of $25.07. The stock’s fifty day simple moving average is $20.65.

Seaport Therapeutics (NASDAQ:SPTX) last announced its earnings results on Monday, August 3rd. The company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($1.07). As a group, sell-side analysts anticipate that Seaport Therapeutics, Inc. will post -4.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. BNP Paribas Exane cut Seaport Therapeutics to a “market perform” rating in a research note on Tuesday, May 26th. Citigroup assumed coverage on shares of Seaport Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $35.00 price objective on the stock. Zacks Research raised shares of Seaport Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Wall Street Zen raised shares of Seaport Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Finally, UBS Group lowered Seaport Therapeutics to a “sell” rating in a report on Tuesday, June 9th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $38.40.

Insider Buying and Selling at Seaport Therapeutics

In related news, Director Robert J. Hombach bought 13,000 shares of the stock in a transaction on Monday, June 22nd. The shares were bought at an average cost of $18.14 per share, for a total transaction of $235,820.00. Following the purchase, the director owned 13,000 shares of the company’s stock, valued at $235,820. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

About Seaport Therapeutics

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.